Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Genetic polymorphisms may serve as prognostic markers for lung cancer

Genetic polymorphisms associated with cancer progression lead to variations in gene expression and may serve as prognostic markers for lung cancer. Researchers at the Hiroshima University and Saitama Medical University found that in patients with lung cancer, a single nucleotide polymorphism (SNP) may regulate gene and protein expression and be associated with poor prognosis.

6 Oct 2015

Algorithm reduces PAH screening costs in systemic sclerosis patients

The Australian Scleroderma Interest Group has derived a screening algorithm for pulmonary arterial hypertension in patients with systemic sclerosis that saves costs by reducing the need for transthoracic echocardiography and right heart catheterisation.

5 Oct 2015

Advanced targeted therapies dominate treatment pipeline for colorectal cancer, finds Frost & Sullivan

A vast number and variety of remedies are steadily joining the treatment pipeline for colorectal cancer. High incidence of the disease, unmet clinical needs, and huge commercial potential are attracting drug developers to the market.

1 Oct 2015

New study finds that serum miRNA profiles change as myeloma progresses

Virtually all patients who develop myeloma have an asymptomatic disease called monoclonal gammopathy of undetermined significance (MGUS) in the years before the onset of myeloma. The five-year relative survival rate for myeloma is 69% for patients diagnosed with stage I or localized disease, compared with 45% for patients with advanced cancer.

30 Sep 2015

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

An international team of cancer researchers that included UT Southwestern Medical Center physicians announced "game-changing results" using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.

29 Sep 2015

Tailorx trial data supports use of Oncotype DX test in patients with early stage breast cancer

Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early stage breast cancer sponsored by the National Cancer Institute, part of the National Institutes of Health, and led by the ECOG-ACRIN Cancer Research Group with support from Genomic Health, Inc.

29 Sep 2015

Study: Biomarkers in maternal blood may predict risk for adverse outcomes in pregnant women with SLE

Pregnant women with systemic lupus erythematosus (SLE), are at higher risk for adverse pregnancy outcomes, including preeclampsia, placental insufficiency, fetal death, miscarriages, and other complications.

29 Sep 2015

OJ-Bio to showcase new smartphone-enabled diagnostic testing device at Medica 2015

Advanced smartphone-enabled medical device technology for the rapid and cost-effective detection of infectious diseases will be featured at this year’s prestigious Medica show.

29 Sep 2015

GENALICE announces global launch date of new analysis module for genomics researchers

Today GENALICE announced the global launch date of Population Calling, a new analysis module and part of their GENALICE MAP Next-Generation Sequencing Data Analysis Suite.

29 Sep 2015

Research posters support utility of EKF’s PointMan DNA enrichment technology for rapid detection of lung cancer mutations

EKF, announces two research posters supporting application of PointMan™ DNA enrichment technology, for rapid and sensitive detection of lung cancer mutations.

From EKF Diagnostics 29 Sep 2015

New targeted therapy shows promise against small cell lung cancer

Small cell lung cancer (SCLC) is an aggressive disease that is difficult to treat and is frequently only diagnosed when it has spread to other parts of the body (metastasised). Five-year survival rates in SCLC, which accounts for about 14% of all lung cancers, are very low, at only six percent. But today US researchers will present two novel findings with important implications for treatment at the 2015 European Cancer Congress.

29 Sep 2015

$Atezolizumab may change treatment strategies for refractory lung cancer patients$

Atezolizumab may change treatment strategies for refractory lung cancer patients

Atezolizumab is set to substantially change treatment strategies for patients with refractory lung cancer, according to Dr Martin Reck, Chief Oncology Physician in the Department of Thoracic Oncology, Hospital Grosshansdorf, Germany. Reck's comments came as the results from the POPLAR and BIRCH studies showing the first results of efficacy with atezolizumab across lines were presented at the European Cancer Congress 2015 (ECC 2015) in Vienna, Austria.

28 Sep 2015

Nivolumab drug significantly prolongs survival in advanced kidney cancer patients

The targeted drug nivolumab significantly prolongs survival in patients with advanced kidney cancer, whose disease has progressed after their first treatment, according to results to be presented at the 2015 European Cancer Congress today (Saturday) and published simultaneously in the New England Journal of Medicine.

26 Sep 2015

Mayo Clinic's Gianrico Farrugia highlights five areas that may impact patient care

How is individualized medicine working? Let us count the ways. That's just what Mayo Clinic Vice President Gianrico Farrugia, M.D., did this morning in his opening keynote at the 4th annual Individualizing Medicine Conference. The core of his talk highlighted five areas in which the knowledge and know-how from the human genome will be most impactful in patient care, not just at Mayo Clinic, but anywhere in the nation and globally.

23 Sep 2015

UCI scientists find potential biomarker for diagnosing certain forms of autism

By identifying a key signaling defect within a specific membrane structure in all cells, University of California, Irvine researchers believe, they have found both a possible reliable biomarker for diagnosing certain forms of autism and a potential therapeutic target.

22 Sep 2015

New cell type appears to drive life-threatening food allergies

Researchers have discovered a new cell type that appears to drive life-threatening food allergies and may help explain why some people get severe allergic reactions and others do not.

22 Sep 2015

Study confirms pathogenic role of beta amyloid in dementia as seen in AD and Down syndrome

More than five million Americans are living with Alzheimer's disease (AD). Of them, 400,000 also have Down syndrome. Both groups have similar looking brains with higher levels of the protein beta amyloid.

18 Sep 2015

Specific biomarker predicts which HER2-negative breast cancer patients respond to targeted therapy

A multicenter team led by Case Western Reserve has demonstrated that brief exposure to a targeted therapy can tell doctors which HER2-negative patients will respond — and which should switch to another kind of treatment.

18 Sep 2015

GENFIT develops reliable, non-invasive diagnostic tool for NASH patients

GENFIT, a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces the development of a new reliable and non-invasive diagnostic method, based on the measurement of a novel type of blood biomarker: small non-coding RNA, or miRNA.

16 Sep 2015

Study reveals how leukemia cells evade deadly effects of BRD4 inhibitors

BRD4 inhibitors are among the most promising new agents in cancer therapy that are currently evaluated in clinical trials.

15 Sep 2015

Biomarker News and Research

Further Reading

Genetic polymorphisms may serve as prognostic markers for lung cancer

Algorithm reduces PAH screening costs in systemic sclerosis patients

Advanced targeted therapies dominate treatment pipeline for colorectal cancer, finds Frost & Sullivan

New study finds that serum miRNA profiles change as myeloma progresses

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

Tailorx trial data supports use of Oncotype DX test in patients with early stage breast cancer

Study: Biomarkers in maternal blood may predict risk for adverse outcomes in pregnant women with SLE

OJ-Bio to showcase new smartphone-enabled diagnostic testing device at Medica 2015

GENALICE announces global launch date of new analysis module for genomics researchers

Research posters support utility of EKF’s PointMan DNA enrichment technology for rapid detection of lung cancer mutations

New targeted therapy shows promise against small cell lung cancer

Atezolizumab may change treatment strategies for refractory lung cancer patients

Nivolumab drug significantly prolongs survival in advanced kidney cancer patients

Mayo Clinic's Gianrico Farrugia highlights five areas that may impact patient care

UCI scientists find potential biomarker for diagnosing certain forms of autism

New cell type appears to drive life-threatening food allergies

Study confirms pathogenic role of beta amyloid in dementia as seen in AD and Down syndrome

Specific biomarker predicts which HER2-negative breast cancer patients respond to targeted therapy

GENFIT develops reliable, non-invasive diagnostic tool for NASH patients

Study reveals how leukemia cells evade deadly effects of BRD4 inhibitors

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo